

1 *Brief Communication*

2 **Early Life Safety Profiling of Gene Therapy for Spinal Muscular Atrophy: A Case Series Analysis**

3 Rebecca G. Spellman^{1,2}, Leillani L. Ha^{1,2}, Salomé Da Silva Duarte Lepez^{1,2}, Elizabeth A. Arruda^{1,2}, Emma
4 Rodrigues^{1,2}, Kathryn J. Swoboda^{1,2,3,*}, Christiano R. R. Alves^{1,2,3,*}

5

6 ¹ Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA

7 ² Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

8 ³ Department of Neurology, Harvard Medical School, Boston, MA, USA

9 *Equal contribution and co-corresponding authors: katswobo@gmail.com and calves2@mgh.harvard.edu

10

11 **Abstract**

12 The present study examines the safety profile of intravenous onasemnogene abeparvovec gene therapy in
13 a real world setting, both alone or in combination with intrathecal antisense oligonucleotide nusinersen
14 therapy in two cohorts of patients with spinal muscular atrophy (SMA). The first cohort included 8
15 presymptomatic infants treated solely with onasemnogene abeparvovec, while the second cohort
16 comprised 6 symptomatic infants receiving onasemnogene abeparvovec and nusinersen co-therapy. All
17 patients received the corticosteroid prednisolone coincident with gene therapy. Circulating alanine
18 aminotransferase (ALT) and aspartate transaminase (AST) levels were measured to determine potential
19 hepatotoxicity, the primary focus of this study. Elevated ALT and AST levels, but no change in GGT levels
20 were observed in 1 pre-symptomatic and 3 symptomatic patients post-treatment. However, all values
21 normalized within three months of onasemnogene abeparvovec injection. Nusinersen treatment received
22 previously or coincident with gene therapy did not impact the elevation of liver transaminases, which was
23 transient. This study highlights the importance of early intervention with molecular treatments for SMA and
24 indicates that prior or coincident treatment with nusinersen is unlikely to impact safety of onasemnogene
25 apoparvovec and could theoretically improve clinical outcomes in symptomatic infants or in those with gene
26 therapy delayed beyond the immediate neonatal period.

27

28 **Keywords:** Neuromuscular diseases; SMA; Neurogenetics; Hepatotoxicity.

29 **Introduction**

30 Molecular therapies have demonstrated remarkable clinical benefits when administered during the pre-
31 symptomatic or early symptomatic stages of spinal muscular atrophy (SMA), significantly improving survival
32 rates even among the most severely affected infants¹. In 2016, nusinersen (Spinraza, Biogen) became the
33 first molecular therapy approved for SMA, and numerous studies have since confirmed its efficacy and
34 safety across various SMA populations^{2,3}. In 2019, the U.S. Food and Drug Administration (FDA) approved
35 onasemnogene abeparvovec (Zolgensma, Novartis/AVXS-101, AveXis), a gene therapy using an adeno-
36 associated virus vector to deliver the SMN1 gene through a single intravenous injection in newborns and
37 infants with SMA. Recent clinical trials have validated the effectiveness of onasemnogene abeparvovec in
38 both pre-symptomatic and symptomatic infants, showing significant motor function improvements⁴⁻⁶. Over
39 the past three years, this has largely become the treatment of choice for monotherapy in newborns with
40 homozygous SMN1 deletion, regardless of SMN2 copy number. While gene therapy is a transformative
41 treatment for SMA, varying adverse effects are observed: most commonly categorized as mild or moderate
42 in severity these adverse events need to be closely monitored⁴⁻⁶. Despite limited data on the safety or long
43 term outcomes of sequential overlapping or combinatorial treatment, there is an increasing number of
44 infants receiving dual or sequential therapy with gene therapy and either nusinersen or risdiplam, an issue
45 not adequately addressed yet in published clinical trials or studies. One of the potentially largest adverse
46 impact on long term efficacy of gene therapy treatment in newborns with 2 SMN2 copies are the delays
47 inherent in obtaining preauthorization, approval, and required preliminary safety testing prior to
48 administration of AAV-9 mediated gene therapy. For a proportion of newborns, their catabolic state, variable
49 transition to appropriate weight gain and social factors in the critical post-partum period, immediate dosing
50 post birth may be neither ideal nor feasible. Thus adequate processes for rapid initiation of an alternative
51 molecular therapy need to be standardized, and would ideally include overlapping coverage through the
52 duration of the viral transduction process post dosing with AAV9-mediated intravenously delivered gene
53 therapy.

54 The most common adverse effect reported with onasemnogene abeparvovec gene therapy is elevated liver
55 enzyme levels, which can indicate acute liver injury^{7,8}. In clinical practice, these elevated levels are usually
56 managed effectively with co-administration of prednisolone, a corticosteroid hormone^{8,9}. Clinical trials have

57 demonstrated that initiating prednisolone 48 hours prior to gene therapy dosing and adjusting as needed
58 for 2-3 months while closely monitoring liver function can successfully avoid serious medical
59 consequences¹⁰. However, further longitudinal research is needed to fully understand the implications and
60 risk of serious consequences at the extremes of age and weight not included in clinical trials.

61 Combinatorial therapies for SMA patients could be used more strategically to facilitate maximum rescue of
62 at-risk motor neurons and other tissues¹¹. The current approach in the clinical setting in the U.S. has been
63 to choose one therapy, and then only consider adding another therapy if the first therapy proves to have
64 insufficient benefit. In newborns identified by newborn screening, timing of gene therapy initiation is
65 variable, but not infrequently delayed several weeks. In an infant with 2 SMN2 copies, this could lead to
66 substantial progression of motor neuron denervation. Nusinersen and onasemnogene abeparvovec act via
67 different molecular mechanisms and display different delivery effectiveness. Nusinersen loading has been
68 associated with dramatic and persistent drop in neurofilament levels in 2 copy infants, and has a long half
69 life that could persist through the gene therapy dosing and transduction process. Thus, in a presymptomatic
70 clinical cohort of infants with 2 SMN2 copies, we hypothesize that sequential administration of nusinersen
71 and onasemnogene abeparvovec could present a synergic effect in these vulnerable SMA infants, without
72 the need to continue long term combinatorial therapy. In already symptomatic 2 copy infants, near
73 simultaneous dosing at the earliest opportunity, as demonstrated in the cohort included here, could
74 maximize survival of the greatest number of at risk motor neurons and help ensure maximal transduction
75 efficacy. Here, we report for the first time a comprehensive safety dataset including the levels of circulating
76 liver enzymes from SMA cases receiving treatment with only onasemnogene abeparvovec, and SMA cases
77 receiving combinatorial therapy with nusinersen and onasemnogene abeparvovec in their first months of
78 life.

79

80 **Methods**

81 This is a longitudinal cohort study including a total of 14 SMA newborns or infants treated in the first months
82 of life at the Massachusetts General Hospital (MGH), including 8 infants who received treatment with
83 onasemnogene abeparvovec and 6 infants who received combinatorial treatment with nusinersen and then

84 onasemnogene abeparvovec. All patients received prednisolone 48 hours prior to onasemnogene
85 abeparvovec dosing and continued for 2-3 months post dosing as per standard of care. None of these
86 patients were receiving risdiplam (Evrysdi, Roche). Of note, all patients receiving only onasemnogene
87 abeparvovec were treated early in life at the pre-symptomatic stage, while all patients receiving co-therapy
88 with nusinersen and onasemnogene abeparvovec in this study demonstrated clinical symptoms at dosing.
89 The primary outcomes of this study are circulating alanine aminotransferase (ALT) and aspartate
90 transaminase (AST) levels measured as biomarkers of potential hepatotoxicity. In addition to the absolute
91 values, the fold change from the baseline (i.e. measurements taken before injection) ALT and AST levels
92 were also calculated for each individual patient and presented. Circulating gamma-glutamyl transferase,
93 troponin T-hs Gen 5 (Troponin T), white blood counts, platelets and albumin levels were also determined
94 as secondary outcomes along with any clinical adverse effect manifestation. Reference normal ranges were
95 determined based on MGH laboratory references. Reference values from the Mayo Clinic and the University
96 of California San Francisco (UCSF) Children's are also provided. *SMN1* and *SMN2* copy numbers were
97 determined using quantitative polymerase chain reaction as previously described¹². All other outcomes
98 were obtained from the clinical laboratory in association with research visits in the SPOT SMA Longitudinal
99 Pediatric Data Repository (LPDR) housed within the Research Electronic Data Capture Web Application at
100 the Newborn Screening Translational Research Network¹³. Written informed parental consent was obtained
101 from all participants under Institutional Ethics Review Board at the MGH (protocol #2016-P000469).
102 Distribution of age range and sex are presented in **Table 1**.

103

104 **Results**

105 We determined circulating ALT and AST levels in two cohorts of SMA patients receiving gene therapy early
106 in life (**Table 1**). The first cohort included 8 SMA infants ages 20 – 190 days old treated at the pre-
107 symptomatic stage. They received only onasemnogene abeparvovec treatment (**Figures 1A-H**). The
108 second cohort included 6 SMA infants and 1 child who received both nusinersen and onasemnogene
109 abeparvovec (**Figures 2A-F**). Only 1 of 8 presymptomatic infants dosed with onasemnogene abeparvovec
110 had elevated circulating ALT and AST levels, occurring within a few days post injection (**Figure 1B**),

111 showing a 20-fold change in ALT and 9-fold change in AST (**Figure 3A-B, 3E-F**). This specific case was a
112 subject with 3 *SMN2* copies. Importantly, increased ALT and AST levels returned to normal within 3 months
113 after the injection (**Figure 1B, 3A-B, 3E-F**). For the second cohort including symptomatic patients with 2
114 *SMN2* copies, we observed 3 out of 6 cases with elevated circulating ALT and AST levels post
115 onasemnogene abeparvovec injection (**Figure 2A-F**). Two patients showed similar changes, both
116 displaying about a 4.5-fold increase in ALT and a 4-to-7-fold increase in AST. Another patient showed a
117 28-fold change in ALT and 6-fold change in AST from baseline (**Figure 3C-D, 3E-F**). Of note, this patient
118 was also the oldest dosed patient. Increased ALT and AST levels also returned to normal levels around 3
119 months after the injection and were maintained at normal ranges during follow-up (**Figure 2A, 2C, 2E, 3C-**
120 **D, 3E-F**). Taken together, these data closely parallel previously published clinical trial data demonstrating
121 that some infants with SMA experience transient hepatotoxicity after gene therapy even when prednisolone
122 is co-administered, but these effects are transient and typically return to normal by three months.
123 Importantly, all enrolled patients had normal albumin levels and no indications of malnutrition or chronic
124 liver disease (**Table 2** and **Supplementary Table 1**).

125 As complementary analysis, we observed increased levels of troponin T and platelets in most of the SMA
126 infants and children (**Table 2** and **Supplementary File 1**), indicating potential myocardial injury and
127 thrombocytosis. These increased levels are most likely part of the natural course of SMA pathophysiology
128 since they were not observed as a direct consequence of any therapy. Other measurements such as
129 circulating white blood counts and platelets also demonstrated some specific values out of normal range
130 during this longitudinal follow-up study, but did not clearly correlate with treatment (**Table 2** and
131 **Supplementary File 1**). Moreover, we observed multiple mild or moderate clinical events during the follow
132 up of this study, but only 4 patients treated with either gene therapy or co-therapy showed at least one
133 severe adverse event related to a cardiac, respiratory, or nutritional issue (**Table 3**). These adverse events
134 were managed in hospital visits. They were not clearly associated with treatment response, and were
135 considered most likely related to the primary underlying diagnosis. Altogether, these findings validate
136 previous evidence showing that patients with SMA need to be closely monitored after transformative gene
137 therapy is administered in the real world clinical setting.

138

139 **Discussion**

140 Taking advantage of our longitudinal database (MGH SPOT SMA LPDR) that includes SMA cases treated
141 early in life with onasemnogene abeparvovec, we were able to evaluate several markers related to the
142 safety of gene therapy. Our findings indicate that some SMA patients can present hepatotoxicity within a
143 few days after receiving the gene therapy. More drastic changes in ALT and AST values were notably
144 observed in patients dosed with gene therapy at an older age in the second cohort in contrast to the first
145 cohort whose age at dosing was younger on average, reemphasizing the importance of initiating therapy in
146 2 *SMN2* copy infants at the earliest opportunity. These effects are transient and return to normal levels
147 within three months post injection. Corroborating these single center observations, a study combining data
148 from 5 previous clinical trials has observed liver-related adverse events in 34% of SMA patients treated
149 with gene therapy⁷. Variable liver response to the gene therapy was also clearly observed in the original
150 trial establishing the single-dose gene therapy for SMA and emphasized the importance of co-treatment
151 with oral prednisolone to mitigate immune-mediated hepatotoxicity⁸. Prednisolone doses can be adjusted
152 when necessary in each specific SMA case⁸. Here, we observed a total of 4 SMA cases suggesting at least
153 transient liver injury in spite of prednisolone treatment, but without any evident long-lasting consequences.

154 We report longitudinal safety data from 6 symptomatic SMA cases with only 2 *SMN2* copies that have been
155 treated with co-therapy with onasemnogene abeparvovec and nusinersen. These patients are achieving
156 motor milestones that were not expected in the natural history of the disease and the present data also
157 suggest that side effects of these therapies are transient and can be controlled by closely monitoring each
158 patient. These results demonstrate the safety for sequential and coincident nusinersen therapy during the
159 induction process for gene therapy. Nusinersen treatment administered pre-gene therapy treatment
160 theoretically provides an advantage over risdiplam, given its prolonged treatment effect following an initial
161 loading period. However, we did not examine the impact or safety of sequential or coincident treatment with
162 risdiplam in this study, and thus our conclusions are limited. In line with our findings, another recent study
163 including 2 SMA cases that received co-therapy with nusinersen and onasemnogene abeparvovec also
164 reported no apparent increased burden of adverse effects¹¹. This possibility of combining therapies for SMA
165 patients has presented itself as particularly interesting for the SMA community. Based on our current data,
166 we advocate for additional studies analyzing different outcomes in SMA patients receiving co-therapies and

167 an open discussion about the advantages and disadvantages of combining these treatments. We
168 hypothesize that there is limited to no benefit in continuing a second therapy once gene therapy has been
169 delivered in a truly presymptomatic infant with 2 copies. However, there may be in an infant with some
170 evident denervation and an emerging clinical phenotype. In our experience, progressive denervation can
171 sometimes occur quite precipitously in a 2 copy infant between ordering and dosing gene therapy. Thus,
172 biomarkers such as CMAP, MUNE, or robust serum biomarkers must be integrated into the current clinical
173 paradigm since clinical exam and even functional motor tests remain insufficient for this purpose.

174 We observed increased troponin T and variable platelet levels in SMA patients, which are markers of
175 increased risk for myocardial injury and thrombocytosis. While damage in motor neurons accounts for the
176 earliest manifestations in SMA infants, evidence indicates that other tissues contribute to the SMA
177 pathophysiology due to the direct effects of SMN deficiency in tissues other than motoneurons, or indirect
178 effects due to the severe denervation status^{14,15}. In this context, a multidisciplinary approach is critical to
179 monitor and provide the best care for SMA patients. Markers assessed in the current study corroborate the
180 premise of systemic disease manifestation and highlight the importance of close monitoring for emergence
181 of disease phenotypes beyond muscle denervation.

182 In summary, this case series analysis study highlights the importance of early intervention with gene therapy
183 and other molecular treatments for SMA and the need for close monitoring of treatment responses beyond
184 muscle denervation in the real world clinical setting.

185

186 **Data Availability Statement**

187 All data relevant to this study are contained within the manuscript.

188

189 **Acknowledgements**

190 We are grateful to all the patients and families who participated in this study.

191

192 **Author Contributions**

193 K.J.S. and C.R.R.A. directed the research project. R.G.S., S.D.L., E.A.A., E.R., and K.J.S. collected clinical
194 data. R.G.S., L.L.H., S.D.L., E.A.A., E.R., K.J.S., and C.R.R.A. analyzed the data and participated in the
195 data interpretation. L.L.H., K.J.S. and C.R.R.A. drafted the manuscript. All authors reviewed and approved
196 the final manuscript.

197

198 **Funding**

199 C.R.R.A. received a fellowship from the MGH ECOR. K.J.S. was funded by NIH NICHD R01HD054599,
200 NIH NINDS R21NS108015, Biogen, and Cure SMA.

201

202 **Ethical Approval**

203 Ethical approval and written informed parental consent were obtained from all participants under
204 Institutional Ethics Review Boards at the Massachusetts General Hospital (protocol 2016P000469).

205

206 **Competing Interests**

207 C.R.R.A. and K.J.S. are inventors on a patent filed by Mass General Brigham that describes genome
208 engineering technologies to treat SMA. K.J.S. was a recipient of a grant from Biogen and received clinical
209 trial funding from AveXis and Biogen. C.R.R.A is a consultant for Biogen and holds stocks in publicly traded
210 companies developing gene therapies. The other authors declare no competing interests.

211

212 **References**

- 213 1. Groen, E. J. N., Talbot, K. & Gillingwater, T. H. Advances in therapy for spinal muscular atrophy:
214 promises and challenges. *Nat. Rev. Neurol.* **14**, 214–224 (2018).
- 215 2. Finkel, R. S. *et al.* Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. *N.*
216 *Engl. J. Med.* **377**, 1723–1732 (2017).
- 217 3. Hagenacker, T. *et al.* Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional,
218 multicentre, observational cohort study. *Lancet Neurol.* **19**, 317–325 (2020).
- 219 4. Strauss, K. A. *et al.* Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2
220 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. *Nat. Med.* **28**, 1381–1389
221 (2022).
- 222 5. Strauss, K. A. *et al.* Onasemnogene abeparvovec for presymptomatic infants with three copies of
223 SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. *Nat. Med.* **28**, 1390–1397
224 (2022).
- 225 6. Day, J. W. *et al.* Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal
226 muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm,
227 multicentre, phase 3 trial. *Lancet Neurol.* **20**, 284–293 (2021).
- 228 7. Chand, D. *et al.* Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101)
229 for the treatment of spinal muscular atrophy. *J. Hepatol.* **74**, 560–566 (2021).
- 230 8. Mendell, J. R. *et al.* Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N. Engl. J.*
231 *Med.* **377**, 1713–1722 (2017).
- 232 9. Al-Zaidy, S. A. & Mendell, J. R. From Clinical Trials to Clinical Practice: Practical Considerations for
233 Gene Replacement Therapy in SMA Type 1. *Pediatr. Neurol.* **100**, 3–11 (2019).
- 234 10. Mendell, J. R. *et al.* Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene
235 Abeparvovec in Spinal Muscular Atrophy. *JAMA Neurol.* **78**, 834 (2021).
- 236 11. Lee, B. H. *et al.* Combination therapy with nusinersen and AVXS-101 in SMA type 1. *Neurology*
237 **93**, 640–641 (2019).
- 238 12. Prior, T. W. *et al.* A Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene. *Am. J. Hum.*
239 *Genet.* **85**, 408–413 (2009).

- 240 13. Alves, C. R. R. *et al.* Implications of circulating neurofilaments for spinal muscular atrophy
241 treatment early in life: A case series. *Mol. Ther. Methods Clin. Dev.* **23**, 524–538 (2021).
- 242 14. Lipnick, S. L. *et al.* Systemic nature of spinal muscular atrophy revealed by studying insurance
243 claims. *PLOS ONE* **14**, e0213680 (2019).
- 244 15. Nery, F. C. *et al.* Impaired kidney structure and function in spinal muscular atrophy. *Neurol.*
245 *Genet.* **5**, e353 (2019).
- 246
247

248 **Figure Legends**

249

250 **Figure 1. Circulating alanine aminotransferase (ALT) and aspartate transaminase (AST) levels in a**
251 **cohort of SMA patients treated at the pre-symptomatic stage with onasemnogene abeparvovec.** Blue
252 line indicates the day of injection. Colored background area indicates normal concentrations expected in
253 sex-matched controls.

254

255 **Figure 2. Circulating alanine aminotransferase (ALT) and aspartate transaminase (AST) levels in a**
256 **cohort of SMA patients treated with nusinersen and onasemnogene abeparvovec.** Blue line indicates
257 the day of onasemnogene abeparvovec injection. Red line indicates the initial nusinersen dose for each
258 case. Colored background area indicates normal ALT and AST concentrations expected in sex-matched
259 controls. Note: Case #9 has initiated nusinersen treatment more than 125 days before the onasemnogene
260 abeparvovec dose.

261

262 **Figure 3. Fold change of circulating alanine aminotransferase (ALT) and aspartate**
263 **transaminase (AST) levels in SMA patients treated with onasemnogene abeparvovec or with**
264 **nusinersen and onasemnogene abeparvovec. a-b,** Cohort receiving onasemnogene abeparvovec
265 monotherapy. **c-d,** Cohort receiving nusinersen and onasemnogene abeparvovec co-therapy. **e-f,** Both
266 cohorts displayed together in the same plot. AST and ALT were normalized based on the baseline (pre
267 treatment) for each patient.

268

269 **Supplementary Information.** The Excel table consists of a comprehensive set of safety lab data for each
270 patient. Reference values for each lab measurement were annotated from Mayo Clinic and UCSF Benioff
271 Children's Hospital.

Table 1. Information of patients with SMA receiving onasemnogene abeparvovec early in life.

Subject	Sex	Age range at dosing (days)	
Onasemnogene abeparvovec monotherapy in presymptomatic newborns and infants up to ~ 6 months of age (n = 8)			
1	F	31-35	
2	M	21-25	
3	F	16-20	
4	F	81-85	
5	F	36-40	
6	M	186-190	
7	F	101-105	
8	M	171-175	
Combinatorial therapy with onasemnogene abeparvovec (AVXS) and nusinersen in a symptomatic cohort (n = 6)			
9	F	Nusinersen: 71-75	AVXS: 936-940
10	F	Nusinersen: 91-95	AVXS: 96-100
11	F	Nusinersen: 46-50	AVXS: 141-145
12	M	Nusinersen: 76-80	AVXS: 81-85
13	M	Nusinersen: 16-20	AVXS: 26-30
14	M	Nusinersen: 6-10	AVXS: 96-100

Table 2. Clinical characteristics of patients with SMA receiving onasemnogene abeparvovec early in life.

Subject	SMN2 (copies)	GGT (U/L)	Troponin T (ng/L)	WBC (K/uL)	Platelets (K/uL)	Albumin (g/dL)	HGB (g/dL)	CK (U/L)	CK-MB (ng/mL)	No. of Adverse Events
Onasemnogene abeparvovec monotherapy in presymptomatic newborns and infants up to ~ 6 months of age (n = 8)										
1	2	14-66	<i>Not tested</i>	6.58-13.16	346-497	3.7-4.8	10.5-13.2	125-618	8.5-32.8	9 (1 SAE)
2	2	10	<50	10.8-11.2	371-378	3.9-4.4	14.1-14.7	<i>Not tested</i>	<i>Not tested</i>	1
3	3	12-76	5	10.40-13.50	365-730	3.8-4.7	9.7-13.7	40-154	3.8-7.1	4
4	3	11-29	7-29	7.06-11.6	319-446	3.7-4.4	9.8-12.1	49-168	3.2-5.9	0
5	3	7-13	<6-25	13.44-19.85	347-609	3.7-4.5	11.2-12	79-82	<i>Not tested</i>	10
6	4+	11-26	7-28	5.61-10.82	422-914	4.0-4.8	8.9-14.3	188	5.8	0
7	3	7-16	6-7	6.02-9.56	363-407	4.2-4.4	10.4-12	95-211	4.4-10.8	9
8	4+	18-34	8-21	3.96-7.48	181-333	4.3-4.6	11.5-12.7	229	10.8	1
Combinatorial therapy with onasemnogene abeparvovec (AVXS) and nusinersen in a symptomatic cohort (n = 6)										
9	2	7-72	19-61	7.23-13.11	156-541	3.5-4.7	9.5-14.8	54-74	5.2-7.9	8 (2 SAEs)
10	2	5-50	33-82	9.74-14.72	318-541	4.1-4.9	10.6-12.9	106-248	9.9	5 (1 SAE)
11	2	6-18	60	6.75-13.50	316-476	4.2-4.7	10.9-13.2	105-150	15.4	16
12	2	8-46	41-90	5.71-10.85	289-423	4.0-5.1	11-14	126-148	15.5-24.6	8
13	2	4-22	42-61	7.07-11.9	267-799	3.3-4.7	9.4-13.8	160-141	<i>Not tested</i>	9 (3 SAEs)
14	2	11-23	25-68	7.04-8.18	199-399	4.0-4.8	10.9-12	<i>Not tested</i>	<i>Not tested</i>	1

GGT: Gamma-glutamyl transferase; Troponin T: Troponin T-hs Gen 5; WBC; White blood cell count. SAE: severe adverse event

Table 3. Summary of adverse events (AEs) in patients with SMA receiving onasemnogene abeparvovec early in life.

	Mild/Moderate	Severe/Hospital Visit Needed	Total	%
Fever	8	1	9	11.4%
GI	9	---	9	11.4%
Cardiac/Acute life threatening	1	1	2	2.5%
Respiratory	6	3	9	11.4%
Orthopedic	5	---	5	6.3%
Nutritional	1	1	2	2.5%
Other	39	4	43	54.4%
TOTAL AEs	69	7	79	
%	87.3%	8.9%		





